Latirab LSR Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, indicated for the management of gastrointestinal disorders characterized by dysmotility and acid-related symptoms. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort associated with functional dyspepsia and gastroparesis. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcer disease, and erosive esophagitis. The synergistic combination of Levosulpiride and Rabeprazole in Latirab LSR Capsule addresses both motility dysfunction and acid hypersecretion, offering comprehensive symptom control. This formulation is typically administered orally once daily before meals, with dosage and duration tailored according to clinical response and physician guidance. Caution is advised in patients with a history of hypersensitivity to either component, and monitoring is recommended for potential side effects such as extrapyramidal symptoms or electrolyte imbalances. Latirab LSR Capsule should be used under medical supervision to optimize therapeutic outcomes and ensure patient safety.